{"entity":{"id":"bim","kind":"target","name":"BIM (BCL2L11)","aka":["BIM","BH3-only protein BIM","BH3","BimEL","BimL","BimS","BCL2 like 11"],"tldr":"BIM is a pro-death protein that leukaemia cells keep clamped by BCL-2. Venetoclax and sonrotoclax are BH3 mimetics: they copy the part of BIM that binds BCL-2, so BIM is released, the mitochondria leak and the cell dies.","summary":"BCL2L11 (chromosome 2q13) encodes BIM, a BCL-2 family protein whose isoforms induce apoptosis and anoikis with differing potency: BimL is more potent than BimEL, the short Bim-alpha isoforms are weaker, and the BimAC and BimABC isoforms cannot induce apoptosis at all (UniProt O43521). The intrinsic apoptosis pathway record places BIM among the BH3-only proteins (with PUMA, NOXA and BAD) that either inhibit BCL-2, BCL-XL and MCL-1 or directly activate BAX and BAK. In OnCo the BH3 mimetics venetoclax and sonrotoclax occupy the BH3-binding groove of BCL-2 so that sequestered BIM and BAX are released, the mitochondrial outer membrane is permeabilised, cytochrome c triggers caspase activation and CLL, AML and mantle-cell lymphoma cells die within hours.","asOf":"2026-09-22","links":[{"label":"HGNC HGNC:994","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:994"},{"label":"UniProt O43521","url":"https://www.uniprot.org/uniprotkb/O43521/entry"},{"label":"NCBI Gene 10018","url":"https://www.ncbi.nlm.nih.gov/gene/10018"}],"tags":["wave5-target"],"related":["venetoclax","sonrotoclax","bcl2","bax"],"cancers":["cll","aml","dlbcl"],"sections":[],"technologies":["bcl2-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["apoptosis-bcl2"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded in this wave: HGNC and UniProt carry no positivity rates and no other source was consulted."],"provenance":{"editedBy":"OnCo content wave 5 (HGNC REST, UniProt REST, corpus drug and pathway records)","editedOn":"2026-09-22"},"symbol":"BCL2L11","hgnc":"HGNC:994","ensembl":"ENSG00000153094","uniprot":"O43521","entrez":"10018","biology":"BIM itself is not a drug target; the drugs mimic its BH3 domain. Sonrotoclax is recorded as more potent and shorter-acting than venetoclax and active against the venetoclax-resistant G101V BCL2 mutation in preclinical models; both need a ramp-up for tumour lysis precautions.","whereFound":["Chronic lymphocytic leukaemia and AML (venetoclax)","Mantle-cell lymphoma and DLBCL (sonrotoclax)"],"targetClass":"other","prevalence":[]},"route":"/targets/bim/","neighbours":{"drug":[{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"target":[{"id":"bax","kind":"target","name":"BAX","route":"/targets/bax/"},{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"}],"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"}],"pathway":[{"id":"apoptosis-bcl2","kind":"pathway","name":"Intrinsic apoptosis (BCL-2 family)","route":"/pathways/apoptosis-bcl2/"}]}}